The Benefits of ACP-01 Stem Cell Therapy: Can it Save Limbs and thereby Lives

The Benefits of ACP-01 Stem Cell Therapy: Can it Save Limbs and thereby Lives? July 5, 2023

Stem cells, the remarkable building blocks of life, possess the unique ability to develop into various specialized cell types in the body, making them crucial for growth, tissue repair, and regeneration. There are two sources of stem cells. Those that come from the patient and those that come from a donor.

There are three primary types of stem cells:

• embryonic stem cells (ESCs)
• adult stem cells (ASCs)
• and induced pluripotent stem cells (iPSCs).

Embryonic stem cells are derived from early-stage embryos and have the broadest differentiation potential, capable of generating any cell type in the body, but they face an ethical and political hurdle.

Adult stem cells reside in specific organs or tissues and contribute to their maintenance and repair. Induced pluripotent stem cells are artificially reprogrammed patient or donor cells that resemble embryonic stem cells. They provide a potential alternative source, but their reprogramming for patient-specific stem cells is years away from producing a product that is proven safe and effective.

Hemostemix's adult-patient-sourced stem cells are one of the most advanced, safe, and successfully used treatments for heart disease and peripheral arterial disease.

Like all stem cells, adult stem cells have the remarkable ability to divide and differentiate into specialized cell types within the same tissue or organ. Thus, they play a crucial role in the body's maintenance and repair processes.

The primary function of Hemostemix' ACP-01 adult cells is to replenish circulation in tissues and organs damaged by a lack of circulation. When an injury occurs like a heart attack, or tissues are damaged from prolonged reduced circulation, ACP-01 transform into the specific cell types needed for repair.

Once injected, ACPs create new circulation as neovascularization at the site of need, and they signal to recruit other stem cells to their location to aid in its regeneration.

One remarkable characteristic of Hemostemix's ACP-01 is the Company's ability to produce identical copies of the patient specific cells at scale. Since the patient is the source of ACP-01, this ensures the ACP-01 cells that are available for tissue repair and regeneration are identical and patient specific.

As the patient's DNA, they contain the embedded coding to home to the site of need, engraft into it, regenerate it, and recruit other stem cells to the task of its regeneration. These signalling characteristics and qualities are not embedded in donor stem cells or iPSCs to the same extent. It is these signaling properties and processes that have set Hemostemix's results apart from its competitors.

Hemostemix' clinical trials data and compassionate treatment experiences, 498 safe treatments to-date, demonstrate that ACP-01 offer patients suffering from ischemia a compassionate treatment to alleviate their condition.

The Company's researchers are also working on NCP-01, completing an animal study to demonstrate NCP-01 can treat chronic pain associated to decreased functionality in the central nervous system. As well, Chris McNorgan, PhD, is working on an initiative to create a license agreement of NCP-01 with Neuralink or its competitors, as Dr. McNorgan's research is directly relatable to neural electrode-based implantation.

In a stroke model, a previous animal study of NCP-01 completed at the Institute of Experimential Medicine, Czech Republic, NCP-01 demonstrated its ability to home to the site of stroke, engraft at the site of stroke, irrespective of three different methods of injection ((i) skin, (ii) muscle (iii) vein).

Like ACP-01, the Company posits that it is NCP-01's homing properties and processes that will better facilitate the implantation and acceptance of electrodes. Both NCP-01 coated electrodes, and homing to the site of implantation will facilitate the electrode's longevity and signaling capacities.

Hemostemix also has patents on the derivation of heart cell precursors (CCP-01) from the same source product, the patient's blood. Like NCP-01, the Company foresees a program, including partnerships, to move CCP-01 into organ grafts, to create a replacement heart that is populated with the patient's own ACP-01 and CCP-01, reducing the likelihood of rejection or the need for immunosuppression.

In this guide, we'll tell you more about the benefits of stem cell therapy and how it can treat the underlying condition.

What is Stem Cell Therapy?

Stem cell therapy is a form of regenerative medicine that works to promote repair of the body. Hemostemix trademarked Your Fountain of Youth™ as it, in a phrase, helps one understand that we can use our own stem cells to maintain our health, or regenerate it when faced with angina, ischemic heart disease, critical limb ischemia, or peripheral arterial disease, for example.

What is the Best Source of Stem Cells?

There are many sources of stem cells. The first question to ask is do they come from your own body, or a donor? Stem cells that come from your own body are adult stem cells, otherwise known as autologous stem cells, verses stem cells that come from a donor, which are allogenic stem cells.

Using your own stem cells has specific advantages. For example, ACP-01 is processed in the patient's blood serum to retain all of the patient's natural signaling processes, which it leverages to home to the site of need, engraft at the site of need, and recruit other stem cells to the site of need to regenerate it.

What are the Benefits of Hemostemix' Stem Cell Therapy?

The benefits that are associated with ACP-01 include enhanced blood flow, improved heart function, healing of ulcerating wounds, saving a limb from amputation, significantly reduced pain associated to wounds that heal, improved exercise capacity and improved quality of life.

1. Enhanced blood flow: ACP-01 therapy improves blood circulation in patients with CLI, PAD, Ischemic and non-Ischemic Cardiomyopathy, and Angina. By injecting autologous (patient's own) stem cells into the affected areas, the treatment intends to promote the formation of new blood vessels and improve blood flow to the tissue or organs that signal they are ischemic .
2. Reduced pain and improved quality of life: CLI, for example, often causes severe pain even at rest and limits mobility, impacting the quality of life for affected individuals. ACP-01 therapy alleviates pain as it promotes wound healing, and improves functional outcomes, which enhances patients' overall quality of life.
3. Non-invasive procedure: ACP-01 is safe as it utilizes the patient's own cells, which are extracted from a small amount of blood obtained through a blood donation-like procedure. This autologous approach reduces the risk of immune rejection, adverse reactions associated with foreign DNA, including difficult to detect diseases.
4. Improved quality of life and long-term benefits: ACP-01 therapy stimulates the formation of new blood vessels, a process known as angiogenesis. 93.5% of treated limbs in a phase II clinical trial were saved from amputation. Improved blood flow to the ischemic limbs provides long-lasting benefits, as it reduced the risk of amputation and improved overall limb function. Saving a limb from amputation is saving a life, as the CLI mortality rate is greater than 60% five years following limb amputation.

Are Recovery Times Fast?

Safe and minimally invasive, a major benefit of ACP-01 is that the process to acquire it, the patient's blood, is a safe outpatient procedure done routinely day after day. There is no hospital visit required and no recovery time required from a blood draw.

As the physician receives ACP-01 in ready to use syringes from Hemostemix, the process to treat a patient for critical limb ischemia can be done in the physician's clinic as an outpatient procedure. Both sourcing the patient's blood and completion of the injections of ACP-01 reduces hospitalizations, significantly reduces procedure costs, while improving the patients' recovery times.

Considering ACP-01 Therapy

What conditions can ACP-01 treat?

If you suffer from conditions such as critical limb ischemia, or peripheral arterial disease, you may want to consider ACP-01 therapy. It is safe, less invasive than stents or bypass surgery, requires very little recovery time, and is available as an exemption approved compassionate treatment in most jurisdictions.

Lastly, ACP-01 may be used consecutively as treatments to promote healing, reduce chronic pain, rebuild functionality, and improve quality of life.

Want to learn more about ACP-01 therapy? Get in touch today to learn more about how we can help meet your needs.

View All News & Media